Lean Body Mass as a Clinical Outcome in Multicentric Castleman’s Disease
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
Clinical Pearls
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
- Lean body mass is an important clinical outcome because it appears to be related to frailty in other literatures.
- The hope is to eventually study the relationship between fatigue, function, and lean body mass in patients on siltuximab.
Recent Videos
Related Content
